Protalix BioTherapeutics, Inc.
PLX · AMEX
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | $2,932 | $8,312 | -$14,927 | -$27,582 |
| Dep. & Amort. | $1,304 | $1,191 | $1,086 | $1,118 |
| Deferred Tax | $236 | -$3,092 | $0 | $0 |
| Stock-Based Comp. | $3,253 | $3,448 | $2,085 | $2,375 |
| Change in WC | $811 | -$10,539 | -$12,015 | $9,901 |
| Other Non-Cash | $138 | -$638 | -$1,229 | $3,903 |
| Operating Cash Flow | $8,674 | -$1,318 | -$25,000 | -$10,285 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | -$1,282 | -$1,149 | -$628 | -$1,459 |
| Net Acquisitions | $0 | $0 | $0 | $0 |
| Inv. Purchases | -$15,000 | -$20,420 | -$16,000 | -$37,835 |
| Inv. Sales/Matur. | $20,420 | $5,000 | $11,000 | $57,835 |
| Other Inv. Act. | $83 | -$142 | $593 | $380 |
| Investing Cash Flow | $4,221 | -$16,711 | -$5,035 | $18,921 |
| Financing Activities | – | – | – | – |
| Debt Repay. | -$20,420 | $0 | $0 | -$34,122 |
| Stock Issued | $3,626 | $23,954 | $8,236 | $46,200 |
| Stock Repurch. | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 |
| Other Fin. Act. | $0 | $712 | $2 | $0 |
| Financing Cash Flow | -$16,794 | $24,666 | $8,238 | $12,078 |
| Forex Effect | $25 | -$114 | -$77 | $6 |
| Net Chg. in Cash | -$3,874 | $6,523 | -$21,874 | $20,720 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $23,634 | $17,111 | $38,985 | $18,265 |
| End Cash | $19,760 | $23,634 | $17,111 | $38,985 |
| Free Cash Flow | $7,392 | -$2,467 | -$25,628 | -$11,744 |